Conference Coverage (ASCO)

Ad5CMV-p53 Has Antitumor Effect in Head and Neck Cancer

Published in Cancer Weekly, July 12th, 1999

A phase II trial demonstrates that intratumorally administered Ad5CMV-p53 gene therapy is well-tolerated and has anti-tumor activity.

Carol M. Bier-Laning, representing colleagues from Rhone-Poulenc Rorer, Pennsylvania, the University of Texas Southwestern Medical Center, and the University of Maryland Greenebaum Cancer Center, presented results from a phase II multi-center study of Ad5CMV-p53 in patients with recurrent squamous cell carcinoma of the head and neck (SCCHN) at the 35th Annual Meeting of the American Society of Clinical Oncology, held May 15-18, 1999, in Atlanta, Georgia (abstract "A Phase II Multi-Center Study of Ad5CMV-p53 Administered Intratumorally to...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (1999-07-12)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry